{"id":34873,"date":"2026-02-11T09:39:00","date_gmt":"2026-02-11T14:39:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=34873"},"modified":"2026-02-11T10:39:48","modified_gmt":"2026-02-11T15:39:48","slug":"complementary-alternative-data-for-biotech-stock-investors","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/complementary-alternative-data-for-biotech-stock-investors\/","title":{"rendered":"Complementary Alternative Data for Biotech Stock Investors"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\"><strong>Executive Summary: The Imperative of the Data Mosaic in Biotech Investing<\/strong> <\/h3>\n\n\n\n<figure class=\"wp-block-image alignright size-medium\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2026\/02\/image-50-300x300.png\" alt=\"\" class=\"wp-image-36531\" srcset=\"https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2026\/02\/image-50-300x300.png 300w, https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2026\/02\/image-50-150x150.png 150w, https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2026\/02\/image-50-768x768.png 768w, https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2026\/02\/image-50.png 1024w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/figure>\n\n\n\n<p>The biopharmaceutical market is unique, with fortunes made and lost on events such as a Phase III clinical trial outcome, a surprising regulatory decision, or the nuanced wording of a single patent claim.<sup>1<\/sup> In this high-stakes environment, intellectual property (IP) is the foundational asset, and patent data has long been the primary tool for investors to evaluate a company&#8217;s defensible revenue stream and future potential. However, relying solely on this information is a fundamentally incomplete strategy that offers a &#8220;rearview mirror perspective&#8221; on a forward-looking industry.<sup>2<\/sup><\/p>\n\n\n\n<p>This report establishes a core thesis: to generate alpha and mitigate risk in the modern biopharma market, investors must augment traditional patent intelligence with a dynamic &#8220;mosaic&#8221; of alternative data. This is defined as any data from nontraditional sources, such as clinical trial registries, real-world prescription data, or expert commentary, that provides real-time, forward-looking insights beyond what is available in standard company filings or broker reports.<sup>3<\/sup><\/p>\n\n\n\n<p>The analysis demonstrates that specific categories of alternative data\u2014Clinical Intelligence, Commercial &amp; Real-World Evidence (RWE), Expert &amp; Key Opinion Leader (KOL) insights, and broader Business Signals\u2014each provide a unique, actionable perspective that complements and contextualizes patent data. The synergistic combination of these data streams, applied through a multi-layered due diligence framework, is the new standard for achieving a competitive advantage. Success in this domain requires navigating significant challenges related to data integration, legal compliance, and the complex ethical considerations inherent in the life sciences.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>The Centrality of Patents and Their Inherent Limitations<\/strong><\/h3>\n\n\n\n<p>In the biopharmaceutical sector, patents are not merely a legal shield; they are the fundamental currency of progress and the very foundation of a company&#8217;s business model.<sup>5<\/sup> Unlike in the technology industry where trade secrets or network effects can provide a sustainable advantage, a drug molecule&#8217;s structure can be reverse-engineered with relative ease.<sup>5<\/sup> A robust patent portfolio is the &#8220;fortress&#8221; that allows a company to recoup the massive research and development (R&amp;D) expenditure required to bring a single drug to market, a process that can exceed $2 billion.<sup>1<\/sup><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>The Strategic Significance of Patent Types<\/strong><\/h4>\n\n\n\n<p>The value of a biopharma company&#8217;s IP is not monolithic. The type of patent protection it secures is a direct declaration of strategic intent.<sup>2<\/sup><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Composition of Matter Patents:<\/strong> These are the most valuable assets, as they protect the core new chemical entity (NCE) itself.<sup>1<\/sup> Their strength and the duration of their remaining term are often the most significant drivers of a small biotech&#8217;s valuation.<sup>1<\/sup><\/li>\n\n\n\n<li><strong>Method of Use Patents:<\/strong> These protect a specific way of using a compound, such as for a particular indication or disease. They are inherently weaker than a composition of matter patent, as a competitor could potentially market the same compound for a different, non-patented use, creating a potential loophole.<sup>2<\/sup><\/li>\n\n\n\n<li><strong>Process Patents:<\/strong> These patents cover a specific method of manufacturing a compound. While often less critical for small molecules where alternative synthesis routes exist, they are a formidable barrier to entry for biosimilar competitors in the complex world of biologics, where the manufacturing process is intimately tied to the final product&#8217;s structure and function.<sup>2<\/sup><\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>The Limitations of Relying on Patent Data Alone<\/strong><\/h4>\n\n\n\n<p>While foundational, patent data provides a limited and often ambiguous picture of a company&#8217;s true value and trajectory.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Legal Ambiguity and Enforceability Gaps:<\/strong> The &#8220;patent pending&#8221; status, while a strategic deterrent, does not bestow any immediate legal rights or full legal protection.<sup>6<\/sup> An inventor cannot sue another party for infringement during this period. Full legal protection, including the right to prevent unauthorized use, only materializes once the patent is officially granted.<sup>6<\/sup> This creates a high-stakes grey area for investors and competitors alike.<\/li>\n\n\n\n<li><strong>Patent Term Erosion vs. Data Exclusivity:<\/strong> A drug patent is typically granted for 20 years from the date of application.<sup>7<\/sup> However, much of this term is eroded by the lengthy and costly clinical trials and regulatory review processes required before the drug can be commercialized.<sup>1<\/sup> This phenomenon is often referred to as the &#8220;patent cliff,&#8221; a moment of profound market disruption when high-margin revenue can drop to zero almost overnight.<sup>8<\/sup> A crucial distinction often overlooked by investors is &#8220;data exclusivity,&#8221; a separate regulatory mechanism that can confer market exclusivity for a specified period by limiting a generic competitor&#8217;s ability to rely on the originator&#8217;s clinical trial data for their own regulatory approval.<sup>7<\/sup> This can effectively extend de facto market exclusivity even for non-patentable drugs or beyond the patent&#8217;s expiry date, a critical factor for valuation.<sup>7<\/sup><\/li>\n\n\n\n<li><strong>The &#8220;Rearview Mirror&#8221; Problem:<\/strong> Patent data is a &#8220;declaration of intent&#8221;.<sup>2<\/sup> It reveals what a company hopes to achieve and protect. However, it provides a &#8220;rearview mirror perspective&#8221; on the innovation landscape that is insufficient for a race that demands a clear view of the road ahead.<sup>2<\/sup> It does not provide real-time information on a drug&#8217;s commercial adoption, patient usage, or the sentiment of key market influencers.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>The New Frontier: A Taxonomy of Complementary Data for Biotech Investing<\/strong><\/h3>\n\n\n\n<p>The most sophisticated players in the biopharma sector now view alternative data not as a supplement but as a primary, integral component of their investment research.<sup>9<\/sup> This data, which is gathered from nontraditional sources, can be categorized into three main subsets: data generated by individuals, business processes, and sensors.<sup>3<\/sup> For the biotech investor, this can be further refined into several actionable categories.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Clinical Intelligence: The Catalyst for Stock Movement<\/strong><\/h4>\n\n\n\n<p>While traditional analysis focuses on the outcome of a Phase III clinical trial, a more nuanced approach leverages clinical data as a powerful predictive tool. Publicly available clinical trial registries provide a treasure trove of information that can act as a &#8220;catalyst event&#8221; for stock movements, often long before official results are announced.<sup>11<\/sup><\/p>\n\n\n\n<p>A profound discovery is that a clinical trial <em>start<\/em> can produce &#8220;highly predictable outcomes&#8221; with an accuracy of over 70% in back-testing.<sup>11<\/sup> This is because the timing of a trial start is more predictable than a final outcome, providing a distinct advantage for investors with a short-term horizon. The predictive model for this catalyst uses factors such as the length of the trial, the company conducting it, the disease area, the phase, and the company&#8217;s stock price trend in the week prior to the trial start.<sup>11<\/sup> This approach allows investors to build and manage a &#8220;selective portfolio&#8221; that has been shown to outperform broader market indices.<sup>11<\/sup> Furthermore, aggregated clinical trial data can be used to generate &#8220;pipeline fitness reports&#8221; that provide a clear picture of a company&#8217;s development pipeline, helping to predict potential mergers and acquisitions (M&amp;A).<sup>11<\/sup><\/p>\n\n\n\n<p>The relationship between clinical trials and intellectual property also creates a complex and risky &#8220;Catch-22&#8221; for inventors.<sup>12<\/sup> Clinical trial data can be considered &#8220;prior art&#8221; that could invalidate a patent, a risk that increases as a trial progresses from Phase I to Phase III.<sup>12<\/sup> This demonstrates a crucial causal link between scientific disclosure and IP protection that must be monitored closely.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Commercial &amp; Real-World Evidence (RWE): Validating the Business Model<\/strong><\/h4>\n\n\n\n<p>Real-world evidence provides a direct, real-time look at a drug&#8217;s commercial performance, allowing investors to move from projecting theoretical sales to observing actual market uptake.<sup>13<\/sup> Data from sources such as Symphony Health Solutions and First Databank allow for real-time tracking of prescription volume, patient adherence, and regional sales.<sup>15<\/sup> This is the most effective way to validate or challenge a company&#8217;s financial guidance and sales forecasts.<sup>13<\/sup><\/p>\n\n\n\n<p>This data can also be used to identify high-growth areas. Recent trends show that spending on specialty drugs, particularly in therapeutic areas like diabetes, oncology, and immunology, has grown significantly and is a major driver of overall drug costs.<sup>18<\/sup> This information allows investors to strategically focus on sectors with proven market demand and significant growth potential.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Expert &amp; Key Opinion Leader (KOL) Intelligence: Gauging Market Acceptance<\/strong><\/h4>\n\n\n\n<p>Key Opinion Leaders (KOLs) are influential figures who shape treatment strategies, patient outcomes, and regulatory acceptance.<sup>21<\/sup> Their opinions can serve as a leading indicator of a drug&#8217;s commercial viability, as a drug with strong clinical data may fail to achieve market success if key experts are unenthusiastic.<sup>23<\/sup><\/p>\n\n\n\n<p>Sentiment analysis of KOL commentary, whether from expert call transcripts, social media, or publications, provides a crucial qualitative layer to the quantitative data.<sup>23<\/sup> This analysis can be used for competitor analysis, identifying potential new product launches, and anticipating shifts in the standard of care.<sup>23<\/sup><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Broader Business Signals: Uncovering Hidden Risks and Priorities<\/strong><\/h4>\n\n\n\n<p>A company&#8217;s R&amp;D spending is a clear proxy for its strategic priorities.<sup>24<\/sup> For example, the United States accounts for nearly half of global R&amp;D spending, and pharmaceutical giants fund over half of all biotech R&amp;D investments.<sup>24<\/sup> However, it is important to note that the relationship between R&amp;D spending and drug approvals is complex and non-linear, with a significant time lag.<sup>25<\/sup><\/p>\n\n\n\n<p>Beyond financial and R&amp;D metrics, investors can use alternative data to uncover operational risks. A due diligence process that goes beyond a standard checklist can reveal critical, hidden risks. For example, a case study demonstrates how an investor uncovered a potential failure risk by identifying a company&#8217;s heavy reliance on a single-source supplier for a critical manufacturing component of a gene therapy.<sup>26<\/sup> This discovery, which was buried in secondary data sets and confidential interviews, allowed the investor to advise the company to diversify its supply chain, mitigating a risk that could have led to significant delays and financial losses.<sup>26<\/sup><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Table 1: The Biopharma Investment Data Matrix<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td>Data Category<\/td><td>Specific Data Type<\/td><td>Example Data Source<\/td><td>Insights Provided<\/td><td>How it Complements Patent Data<\/td><\/tr><tr><td><strong>Clinical Intelligence<\/strong><\/td><td>Trial starts, outcomes, recruitment data, pipeline metrics<\/td><td>ClinicalTrials.gov, proprietary databases (e.g., Ozmosi)<\/td><td>Predictive signals for stock catalysts; pipeline strength; M&amp;A likelihood; risk of patent invalidation<\/td><td>Provides a forward-looking view of what a company <em>is doing<\/em> with its patented technology, complementing the static view of what it <em>owns<\/em><\/td><\/tr><tr><td><strong>Commercial &amp; RWE<\/strong><\/td><td>Prescription volume, claims data, patient adherence, payer analytics<\/td><td>Symphony Health, First Databank, IQVIA, Clarivate<\/td><td>Real-time sales validation; market uptake; pricing pressures; competitive landscape shifts<\/td><td>Moves from a theoretical, patent-protected revenue forecast to observing actual market performance and commercial viability<\/td><\/tr><tr><td><strong>Expert &amp; KOL Intelligence<\/strong><\/td><td>Expert call transcripts, interviews, social media commentary, publications<\/td><td>AlphaSense, proprietary platforms (e.g., ExtendMed, Excelra)<\/td><td>Qualitative sentiment on a drug; market acceptance; new product launches; competitor strategies<\/td><td>Gauges the likelihood of a drug&#8217;s commercial adoption, providing a crucial qualitative layer to a quantitative IP analysis<\/td><\/tr><tr><td><strong>Broader Business Signals<\/strong><\/td><td>R&amp;D spending, capital allocation, supply chain data, job listings<\/td><td>Public filings, industry reports, web scraping, proprietary data feeds (e.g., Thinknum)<\/td><td>Uncovers hidden operational risks (e.g., single-source suppliers); strategic priorities; financial health; burn rate<\/td><td>Provides a view of the operational and corporate realities behind the IP, identifying risks that could undermine the value of a patent portfolio<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Synthesizing the Mosaic: A Multi-Layered Framework for Due Diligence<\/strong><\/h3>\n\n\n\n<p>For a biotech investor, a successful due diligence process is guided by a &#8220;Mosaic Theory of Investing,&#8221; which involves finding investment opportunities by combining a diverse array of information sources.<sup>27<\/sup> This means synthesizing traditional, dense IP data with a wide array of unstructured and real-time alternative data to create a comprehensive picture of an investment opportunity. A rigorous, multi-layered framework is essential to put this theory into practice.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Layer 1: Foundational Legal &amp; IP Analysis<\/strong><\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Purpose:<\/strong> To validate the legal standing and defensibility of a company&#8217;s core intellectual property.<sup>28<\/sup><\/li>\n\n\n\n<li><strong>Data:<\/strong> This layer requires a deep dive into patent filings, court dockets, litigation databases, and IP analytics platforms such as DrugPatentWatch or IQVIA.<sup>1<\/sup><\/li>\n\n\n\n<li><strong>Key Questions:<\/strong> Is the ownership (&#8220;chain of title&#8221;) of the patents clear and undisputed? Is the patent&#8217;s scope broad enough to prevent competitors from easily designing around it? Are there active challenges or litigation risks that could invalidate the patent?<sup>1<\/sup> A legally strong patent portfolio may be strategically weak if it is concentrated in a jurisdiction facing new price controls or tariffs, which underscores the need to integrate geopolitical analysis into the evaluation.<sup>28<\/sup><\/li>\n\n\n\n<li><strong>Layer 2: Scientific &amp; Clinical Validation<\/strong><\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Purpose:<\/strong> To de-risk the scientific rationale and assess the clinical efficacy of a drug candidate.<sup>30<\/sup><\/li>\n\n\n\n<li><strong>Data:<\/strong> This layer relies on public and proprietary clinical trial databases, expert call transcripts, and scientific literature that may precede patent filings.<sup>1<\/sup><\/li>\n\n\n\n<li><strong>Key Questions:<\/strong> Does the product candidate address a significant unmet medical need?<sup>30<\/sup> Does the preclinical data support the claims, and how does that data translate to human trials? Is there a risk that the trials themselves could be considered &#8220;public use&#8221; and thus invalidate the patents?<sup>12<\/sup> A case study of a venture capital firm demonstrates the value of this layer: the team went beyond a standard checklist to analyze a subtle data anomaly\u2014inconsistent tumor regression in mice models\u2014and discovered a potential &#8220;human-specific efficacy&#8221; that had been buried in secondary data.<sup>26<\/sup> This shows that a deep, expert-led qualitative analysis of seemingly minor details can uncover a hidden breakthrough.<\/li>\n\n\n\n<li><strong>Layer 3: Commercial &amp; Market Opportunity Analysis<\/strong><\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Purpose:<\/strong> To quantify the market opportunity and validate the commercial viability of a product.<sup>13<\/sup><\/li>\n\n\n\n<li><strong>Data:<\/strong> This layer leverages prescription and claims data, market access reports, and KOL sentiment analysis platforms.<sup>13<\/sup><\/li>\n\n\n\n<li><strong>Key Questions:<\/strong> What is the true patient population and addressable market size? Is the drug&#8217;s uptake in line with company projections, or are there discrepancies between guidance and real-world prescription volume? How do its pricing and reimbursement strategies compare to those of competitors, and are there potential hurdles to market access?<sup>8<\/sup><\/li>\n\n\n\n<li><strong>Layer 4: Corporate &amp; Operational Health<\/strong><\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Purpose:<\/strong> To assess a company&#8217;s financial health, strategic priorities, and operational risks.<sup>24<\/sup><\/li>\n\n\n\n<li><strong>Data:<\/strong> This layer includes R&amp;D spending trends, capital allocation data, and supply chain analysis.<sup>24<\/sup><\/li>\n\n\n\n<li><strong>Key Questions:<\/strong> Is the company&#8217;s capital allocation aligned with its stated goals? Is its financial &#8220;burn rate&#8221; sustainable given its pipeline? Are there hidden operational dependencies, such as a reliance on a single-source supplier for a critical component, that could lead to significant delays or even failure?<sup>26<\/sup><\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Table 2: Integrated Due Diligence Checklist<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td>Due Diligence Layer<\/td><td>Key Question to Answer<\/td><td>Relevant Data Sources<\/td><td>Potential Risk Identified<\/td><\/tr><tr><td><strong>Foundational Legal &amp; IP<\/strong><\/td><td>Is the core composition of matter patent valid, enforceable, and broad enough to prevent competitors from designing around it?<\/td><td>Patent filings, litigation databases, court dockets, IP analytics platforms (e.g., DrugPatentWatch, IQVIA)<\/td><td>Patent validity challenges (e.g., IPRs), narrow claim scope, ongoing litigation, unclear chain of title<\/td><\/tr><tr><td><strong>Scientific &amp; Clinical<\/strong><\/td><td>Does the preclinical data strongly support the drug&#8217;s mechanism of action, and are there hidden risks in the clinical trial design?<\/td><td>Clinical trial registries, scientific publications, expert call transcripts, non-human trial data<\/td><td>Inconsistent efficacy signals, risk of trial data being considered prior art, flawed trial design that could lead to failure<\/td><\/tr><tr><td><strong>Commercial &amp; Market<\/strong><\/td><td>Is the drug&#8217;s projected market uptake and pricing realistic, and is it gaining traction with key market influencers?<\/td><td>Prescription\/claims data, payer reports, market access portals, KOL sentiment analysis<\/td><td>Mismatch between sales guidance and real-world uptake, unfavorable reimbursement policies, lack of acceptance by influential practitioners<\/td><\/tr><tr><td><strong>Corporate &amp; Operational<\/strong><\/td><td>Is the company&#8217;s capital allocation efficient, and are there hidden operational dependencies that could compromise its progress?<\/td><td>R&amp;D spending trends, debt\/equity issuance, supply chain documentation, confidential interviews<\/td><td>Unsustainable cash burn rate, single-source supplier risk, supply chain disruptions, unaligned corporate strategy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Navigating the Minefield: Challenges, Risks, and Ethical Considerations<\/strong><\/h3>\n\n\n\n<p>Despite its immense potential, the use of alternative data in biopharma investing is not without significant challenges and risks.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>The Challenges of Alternative Data<\/strong><\/h4>\n\n\n\n<p>The first hurdle is the sheer cost and complexity associated with data integration.<sup>33<\/sup> Alternative data often comes from &#8220;unconventional sources&#8221; with a &#8220;lack of consistent formats,&#8221; creating significant challenges for quality control and integration.<sup>33<\/sup> The biotech sector&#8217;s data is particularly fragmented, with inconsistent data types and an absence of standardized models, which necessitates complex and costly data cleansing and transformation processes.<sup>34<\/sup><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Ethical and Regulatory Risks: The New Due Diligence Frontier<\/strong><\/h4>\n\n\n\n<p>Beyond the technical challenges, the handling of sensitive patient and genetic data introduces significant ethical and regulatory risks that can have a direct impact on a company&#8217;s valuation and long-term viability.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Data Privacy as a Valuation Risk:<\/strong> The misuse of sensitive data is not just an ethical concern but a direct financial and legal risk.<sup>35<\/sup> Non-compliance with stringent regulations like the Health Insurance Portability and Accountability Act (HIPAA) in the U.S. or the General Data Protection Regulation (GDPR) in the EU can result in &#8220;steep fines, legal complications, and a severe loss of trust&#8221; among patients and providers.<sup>36<\/sup><\/li>\n\n\n\n<li><strong>The Risk of Algorithmic Bias:<\/strong> The widespread adoption of AI in biotech raises concerns about algorithmic bias, which occurs when AI systems produce &#8220;skewed results&#8221; due to a lack of diverse and representative training data.<sup>35<\/sup> This can lead to misdiagnoses or ineffective treatments for underrepresented populations, which can erode trust and lead to legal challenges.<sup>35<\/sup> For an investor, a company&#8217;s adherence to responsible AI development is no longer a secondary concern but a key component of risk management.<sup>37<\/sup><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Conclusion and Recommendations<\/strong><\/h3>\n\n\n\n<p>The era of relying solely on traditional financial and patent data to invest in biopharma is over. The sector is defined by a unique set of risks that demand a nuanced, data-driven approach. The synergistic combination of patent intelligence with a mosaic of alternative data provides a path to identifying alpha and de-risking investments by offering a forward-looking, real-time, and holistic view of an opportunity.<\/p>\n\n\n\n<p>The following recommendations are crucial for investors seeking to adopt this new standard:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Build a Data Strategy, Not a Data Pile:<\/strong> Instead of opportunistically acquiring data, a structured, repeatable process is essential. This involves understanding what information is needed to answer specific investment questions and then sourcing the data to meet those needs.<\/li>\n\n\n\n<li><strong>Invest in Integration:<\/strong> The cost and complexity of data integration are significant hurdles, but they are a necessary investment for a competitive edge. The ability to harmonize disparate datasets is a foundational requirement for a modern investment firm.<\/li>\n\n\n\n<li><strong>Prioritize Vendor Compliance:<\/strong> Investors should perform thorough and systematic due diligence on their data and AI vendors.<sup>37<\/sup> A vendor&#8217;s ability to demonstrate clear data provenance and adherence to ethical and regulatory standards is a key component of mitigating legal and reputational risk.<sup>37<\/sup><\/li>\n\n\n\n<li><strong>Cultivate In-House Expertise:<\/strong> Effectively interpreting and synthesizing these complex data streams requires a multidisciplinary team. A &#8220;carefully orchestrated collaboration of specialists&#8221; with legal, scientific, clinical, and technical expertise is essential to move beyond a simple checklist and uncover hidden breakthroughs and failures.<sup>28<\/sup><\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Table 3: Key Alternative Data Providers for Biopharma<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td>Provider<\/td><td>Data\/Service Category<\/td><td>Key Use Case<\/td><\/tr><tr><td><strong>DrugPatentWatch<\/strong><\/td><td>Patent Intelligence, IP analytics<\/td><td>Evaluate branded and generic market opportunities, track litigation, and backtest financial models with historical data <sup>29<\/sup><\/td><\/tr><tr><td><strong>IQVIA<\/strong><\/td><td>Patent and Commercial Intelligence, RWE<\/td><td>Assess patent expirations and prepare for generic entry; model impact scenarios; analyze prescription and market data <sup>15<\/sup><\/td><\/tr><tr><td><strong>Ozmosi<\/strong><\/td><td>Clinical Trial Intelligence<\/td><td>Predict stock movements based on clinical trial starts; generate pipeline fitness reports for M&amp;A analysis <sup>11<\/sup><\/td><\/tr><tr><td><strong>Symphony Health Solutions<\/strong><\/td><td>Prescription and Claims Data, RWE<\/td><td>Track prescription volume and gross sales for U.S. marketed drugs; validate revenue forecasts <sup>15<\/sup><\/td><\/tr><tr><td><strong>Clarivate<\/strong><\/td><td>Commercialization, Market Access<\/td><td>Streamline managed markets data, secure and optimize market access, and determine addressable patient populations <sup>31<\/sup><\/td><\/tr><tr><td><strong>MiBA Analytics<\/strong><\/td><td>Oncology RWE, AI-Powered Analytics<\/td><td>Gain real-time visibility into oncology care; access comprehensive, de-identified patient data across the treatment journey <sup>40<\/sup><\/td><\/tr><tr><td><strong>Paragon Intel<\/strong><\/td><td>Real-World Evidence, Patient Data<\/td><td>Obtain granular insights into product revenue and market share; monitor patient volumes and treatment patterns <sup>13<\/sup><\/td><\/tr><tr><td><strong>Excelra<\/strong><\/td><td>KOL Intelligence<\/td><td>Identify and build comprehensive databases of Key Opinion Leaders (KOLs) with a unique eminence score <sup>22<\/sup><\/td><\/tr><tr><td><strong>PlexoA<\/strong><\/td><td>Qualitative Due Diligence<\/td><td>Uncover hidden breakthroughs or failures through advanced qualitative analysis of subtle data anomalies during due diligence <sup>26<\/sup><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Works cited<\/strong><\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Leveraging Drug Patent Data for Strategic Investment Decisions: A Comprehensive Analysis, accessed August 20, 2025, <a href=\"https:\/\/www.drugpatentwatch.com\/blog\/leveraging-drug-patent-data-for-strategic-investment-decisions-a-comprehensive-analysis\/\">https:\/\/www.drugpatentwatch.com\/blog\/leveraging-drug-patent-data-for-strategic-investment-decisions-a-comprehensive-analysis\/<\/a><\/li>\n\n\n\n<li>Beyond the Bench: Transforming Biopharmaceutical Strategy with &#8230;, accessed August 20, 2025, <a href=\"https:\/\/www.drugpatentwatch.com\/blog\/beyond-the-bench-transforming-biopharmaceutical-strategy-with-patent-intelligence\/\">https:\/\/www.drugpatentwatch.com\/blog\/beyond-the-bench-transforming-biopharmaceutical-strategy-with-patent-intelligence\/<\/a><\/li>\n\n\n\n<li>Alternative Data Sources for Investment &amp; Market Research, accessed August 20, 2025, <a href=\"https:\/\/www.alpha-sense.com\/solutions\/alternative-data\/\">https:\/\/www.alpha-sense.com\/solutions\/alternative-data\/<\/a><\/li>\n\n\n\n<li>What Is Alternative Data? &#8211; Investopedia, accessed August 20, 2025, <a href=\"https:\/\/www.investopedia.com\/what-is-alternative-data-6889002\">https:\/\/www.investopedia.com\/what-is-alternative-data-6889002<\/a><\/li>\n\n\n\n<li>The Alchemist&#8217;s Playbook: Transforming Drug Patent Data into Financial Gold with Advanced IP Valuation and Financing Models &#8211; DrugPatentWatch, accessed August 20, 2025, <a href=\"https:\/\/www.drugpatentwatch.com\/blog\/the-alchemists-playbook-transforming-drug-patent-data-into-financial-gold-with-advanced-ip-valuation-and-financing-models\/\">https:\/\/www.drugpatentwatch.com\/blog\/the-alchemists-playbook-transforming-drug-patent-data-into-financial-gold-with-advanced-ip-valuation-and-financing-models\/<\/a><\/li>\n\n\n\n<li>Strategic Imperatives: Leveraging Patent Pending Data for &#8230;, accessed August 20, 2025, <a href=\"https:\/\/www.drugpatentwatch.com\/blog\/leveraging-patent-pending-data-for-pharmaceuticals\/\">https:\/\/www.drugpatentwatch.com\/blog\/leveraging-patent-pending-data-for-pharmaceuticals\/<\/a><\/li>\n\n\n\n<li>Raising the Barriers to Access to Medicines in the Developing World \u2013 The Relentless Push for Data Exclusivity &#8211; PMC &#8211; PubMed Central, accessed August 20, 2025, <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5347964\/\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5347964\/<\/a><\/li>\n\n\n\n<li>Valuation of Pharma Companies: 5 Key Considerations &#8211; DrugPatentWatch, accessed August 20, 2025, <a href=\"https:\/\/www.drugpatentwatch.com\/blog\/valuation-of-pharma-companies-5-key-considerations-2\/\">https:\/\/www.drugpatentwatch.com\/blog\/valuation-of-pharma-companies-5-key-considerations-2\/<\/a><\/li>\n\n\n\n<li>\u201c$1.72 Billion\u201d: How Alternative Data Is Transforming Investment Research &#8211; SG Analytics, accessed August 20, 2025, <a href=\"https:\/\/www.sganalytics.com\/blog\/1-72-billion-how-alternative-data-is-transforming-investment-research\/\">https:\/\/www.sganalytics.com\/blog\/1-72-billion-how-alternative-data-is-transforming-investment-research\/<\/a><\/li>\n\n\n\n<li>Top 10 Alternative Data Use Cases for Investment in 2025 &#8211; Research AIMultiple, accessed August 20, 2025, <a href=\"https:\/\/research.aimultiple.com\/alternative-data-use-cases\/\">https:\/\/research.aimultiple.com\/alternative-data-use-cases\/<\/a><\/li>\n\n\n\n<li>A NEW CATALYST EVENT UNCOVERED FOR &#8230; &#8211; Ozmosi, accessed August 20, 2025, <a href=\"https:\/\/www.ozmosi.com\/wp-content\/uploads\/2022\/09\/Trial-Start-Catalyst-and-Portfolio-Approach-OZMOSI.pdf\">https:\/\/www.ozmosi.com\/wp-content\/uploads\/2022\/09\/Trial-Start-Catalyst-and-Portfolio-Approach-OZMOSI.pdf<\/a><\/li>\n\n\n\n<li>Can Clinical Trials Negate Patentability for Pharma Inventions? &#8211; Fish &amp; Richardson, accessed August 20, 2025, <a href=\"https:\/\/www.fr.com\/insights\/thought-leadership\/blogs\/can-clinical-trials-negate-patentability-for-pharma-inventions\/\">https:\/\/www.fr.com\/insights\/thought-leadership\/blogs\/can-clinical-trials-negate-patentability-for-pharma-inventions\/<\/a><\/li>\n\n\n\n<li>Data for Life Sciences Investors: Top Alternative Data Providers &#8230;, accessed August 20, 2025, <a href=\"https:\/\/paragonintel.com\/data-for-life-sciences-investors-top-alternative-data-providers\/\">https:\/\/paragonintel.com\/data-for-life-sciences-investors-top-alternative-data-providers\/<\/a><\/li>\n\n\n\n<li>Pharma Commercial Analytics: Drive Smarter Decisions in 2025 &#8211; Viseven, accessed August 20, 2025, <a href=\"https:\/\/viseven.com\/guide-to-commercial-analytics-in-pharma\/\">https:\/\/viseven.com\/guide-to-commercial-analytics-in-pharma\/<\/a><\/li>\n\n\n\n<li>Bloomberg for biotech &amp; pharma corporations., accessed August 20, 2025, <a href=\"https:\/\/data.bloomberglp.com\/professional\/sites\/10\/783359_AUD_CORP_HealthCare_BCH_DIG-1.pdf\">https:\/\/data.bloomberglp.com\/professional\/sites\/10\/783359_AUD_CORP_HealthCare_BCH_DIG-1.pdf<\/a><\/li>\n\n\n\n<li>Healthcare | Symphony, accessed August 20, 2025, <a href=\"https:\/\/symphony.is\/work\/industries\/healthcare\">https:\/\/symphony.is\/work\/industries\/healthcare<\/a><\/li>\n\n\n\n<li>Drug Database | Medication Decision Support | FDB (First Databank), accessed August 20, 2025, <a href=\"https:\/\/www.fdbhealth.com\/\">https:\/\/www.fdbhealth.com\/<\/a><\/li>\n\n\n\n<li>Trends in Prescription Drug Spending, 2016-2021 &#8211; HHS ASPE, accessed August 20, 2025, <a href=\"https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/88c547c976e915fc31fe2c6903ac0bc9\/sdp-trends-prescription-drug-spending.pdf\">https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/88c547c976e915fc31fe2c6903ac0bc9\/sdp-trends-prescription-drug-spending.pdf<\/a><\/li>\n\n\n\n<li>FLASH | 2025 Drug Trend &amp; Pipeline &#8211; Mercer Government, accessed August 20, 2025, <a href=\"https:\/\/www.mercer-government.mercer.com\/our-insights\/2025-Drug-Trend-and-Pipeline.html\">https:\/\/www.mercer-government.mercer.com\/our-insights\/2025-Drug-Trend-and-Pipeline.html<\/a><\/li>\n\n\n\n<li>Medical cost trend: Behind the numbers &#8211; PwC, accessed August 20, 2025, <a href=\"https:\/\/www.pwc.com\/us\/en\/industries\/health-industries\/library\/behind-the-numbers.html\">https:\/\/www.pwc.com\/us\/en\/industries\/health-industries\/library\/behind-the-numbers.html<\/a><\/li>\n\n\n\n<li>KOL Management in Pharma: A Complete Guide (2025) &#8211; ExtendMed, accessed August 20, 2025, <a href=\"https:\/\/www.extendmed.com\/news-and-resources\/kol-management\">https:\/\/www.extendmed.com\/news-and-resources\/kol-management<\/a><\/li>\n\n\n\n<li>Data Insights &#8211; Excelra, accessed August 20, 2025, <a href=\"https:\/\/www.excelra.com\/our-services\/data\/healthcare-data-structuring\/\">https:\/\/www.excelra.com\/our-services\/data\/healthcare-data-structuring\/<\/a><\/li>\n\n\n\n<li>The Importance of KOL Sentiment Analysis &#8211; Clear Point Health, accessed August 20, 2025, <a href=\"https:\/\/www.clearpointhealth.com\/blog\/the-importance-of-kol-sentiment-analysis-wyf9f\">https:\/\/www.clearpointhealth.com\/blog\/the-importance-of-kol-sentiment-analysis-wyf9f<\/a><\/li>\n\n\n\n<li>Biotech R&amp;D Spending: Who&#8217;s Investing the Most in New Drug Discovery? (Market Trends), accessed August 20, 2025, <a href=\"https:\/\/patentpc.com\/blog\/biotech-rd-spending-whos-investing-the-most-in-new-drug-discovery-market-trends\">https:\/\/patentpc.com\/blog\/biotech-rd-spending-whos-investing-the-most-in-new-drug-discovery-market-trends<\/a><\/li>\n\n\n\n<li>Research and Development in the Pharmaceutical Industry | Congressional Budget Office, accessed August 20, 2025, <a href=\"https:\/\/www.cbo.gov\/publication\/57126\">https:\/\/www.cbo.gov\/publication\/57126<\/a><\/li>\n\n\n\n<li>Case Study Report: Uncovering Hidden Breakthroughs and Failures in Biotech Due Diligence &#8211; PlexoA, accessed August 20, 2025, <a href=\"https:\/\/plexoa.com\/case-study-report-uncovering-hidden-breakthroughs-and-failures-in-biotech-due-diligence\/\">https:\/\/plexoa.com\/case-study-report-uncovering-hidden-breakthroughs-and-failures-in-biotech-due-diligence\/<\/a><\/li>\n\n\n\n<li>How to Use Alternative Data for Investment Decisions &#8211; Exploding Topics, accessed August 20, 2025, <a href=\"https:\/\/explodingtopics.com\/blog\/alternative-data-investment-decisions\">https:\/\/explodingtopics.com\/blog\/alternative-data-investment-decisions<\/a><\/li>\n\n\n\n<li>A Comprehensive Guide to Pharmaceutical Patent Due Diligence in Mergers &amp; Acquisitions, accessed August 20, 2025, <a href=\"https:\/\/www.drugpatentwatch.com\/blog\/ma-patent-due-diligence-comprehensive-guide\/\">https:\/\/www.drugpatentwatch.com\/blog\/ma-patent-due-diligence-comprehensive-guide\/<\/a><\/li>\n\n\n\n<li>Alternative Data for Biotechnology and Pharmaceutical Financial Modeling and Time Series Analysis &#8211; DrugPatentWatch, accessed August 20, 2025, <a href=\"https:\/\/www.drugpatentwatch.com\/financial-modeling.php\/\">https:\/\/www.drugpatentwatch.com\/financial-modeling.php\/<\/a><\/li>\n\n\n\n<li>1 FIRST PRINCIPLES OF R&amp;D \u2013 THE ROLE OF DUE DILIGENCE &#8211; Novina Lab, accessed August 20, 2025, <a href=\"https:\/\/novinalab.dana-farber.org\/uploads\/1\/1\/2\/8\/112805345\/01_mermelstein_layout_1.pdf\">https:\/\/novinalab.dana-farber.org\/uploads\/1\/1\/2\/8\/112805345\/01_mermelstein_layout_1.pdf<\/a><\/li>\n\n\n\n<li>Pharma Market Access &amp; Sizing Data Solutions | Clarivate, accessed August 20, 2025, <a href=\"https:\/\/clarivate.com\/life-sciences-healthcare\/commercialization\/market-access\/\">https:\/\/clarivate.com\/life-sciences-healthcare\/commercialization\/market-access\/<\/a><\/li>\n\n\n\n<li>Tips for Preparing Biotechnology Companies for Their First Financing Round, accessed August 20, 2025, <a href=\"https:\/\/www.morganlewis.com\/blogs\/asprescribed\/2023\/09\/tips-for-preparing-biotechnology-companies-for-their-first-financing-round\">https:\/\/www.morganlewis.com\/blogs\/asprescribed\/2023\/09\/tips-for-preparing-biotechnology-companies-for-their-first-financing-round<\/a><\/li>\n\n\n\n<li>Alternative Data Market Size, Share | CAGR of 51.5%, accessed August 20, 2025, <a href=\"https:\/\/market.us\/report\/alternative-data-market\/\">https:\/\/market.us\/report\/alternative-data-market\/<\/a><\/li>\n\n\n\n<li>Exploring Biotech Data Challenges and Solutions: Unveiling Scispot Rooms |, accessed August 20, 2025, <a href=\"https:\/\/www.scispot.com\/blog\/biotech-data-challenges-and-solutions\">https:\/\/www.scispot.com\/blog\/biotech-data-challenges-and-solutions<\/a><\/li>\n\n\n\n<li>Ethics and AI in Biotech: Navigating Data Privacy &#8230; &#8211; Allied Academies, accessed August 20, 2025, <a href=\"https:\/\/www.alliedacademies.org\/articles\/ethics-and-ai-in-biotech-navigating-data-privacy-and-algorithmic-bias.pdf\">https:\/\/www.alliedacademies.org\/articles\/ethics-and-ai-in-biotech-navigating-data-privacy-and-algorithmic-bias.pdf<\/a><\/li>\n\n\n\n<li>Navigating Data Privacy in Biotech Marketing: Locking Down vs. Expanding Market Reach, accessed August 20, 2025, <a href=\"https:\/\/zozimus.com\/navigating-data-privacy-in-biotech-marketing-locking-down-vs-expanding-market-reach\/\">https:\/\/zozimus.com\/navigating-data-privacy-in-biotech-marketing-locking-down-vs-expanding-market-reach\/<\/a><\/li>\n\n\n\n<li>Key Considerations for Alternative Data and AI Vendors to Investment Firms: Demonstrating Compliance in the Face of an Evolving Regulatory Environment | Lowenstein Sandler LLP, accessed August 20, 2025, <a href=\"https:\/\/www.lowenstein.com\/news-insights\/publications\/articles\/key-considerations-for-alternative-data-and-ai-vendors-to-investment-firms-demonstrating-compliance-in-the-face-of-an-evolving-regulatory-environment\">https:\/\/www.lowenstein.com\/news-insights\/publications\/articles\/key-considerations-for-alternative-data-and-ai-vendors-to-investment-firms-demonstrating-compliance-in-the-face-of-an-evolving-regulatory-environment<\/a><\/li>\n\n\n\n<li>DrugPatentWatch is a time-saving powerhouse, accessed August 20, 2025, <a href=\"https:\/\/www.drugpatentwatch.com\/\">https:\/\/www.drugpatentwatch.com\/<\/a><\/li>\n\n\n\n<li>Patent Intelligence &#8211; IQVIA, accessed August 20, 2025, <a href=\"https:\/\/www.iqvia.com\/solutions\/commercialization\/commercial-analytics-and-consulting\/brand-strategy-and-management\/patent-intelligence\">https:\/\/www.iqvia.com\/solutions\/commercialization\/commercial-analytics-and-consulting\/brand-strategy-and-management\/patent-intelligence<\/a><\/li>\n\n\n\n<li>Meaningful Insights Biotech Analytics: MiBA, accessed August 20, 2025, <a href=\"https:\/\/www.mibanalytics.com\/\">https:\/\/www.mibanalytics.com\/<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Executive Summary: The Imperative of the Data Mosaic in Biotech Investing The biopharmaceutical market is unique, with fortunes made and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":36531,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-34873","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/34873","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=34873"}],"version-history":[{"count":3,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/34873\/revisions"}],"predecessor-version":[{"id":36532,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/34873\/revisions\/36532"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/36531"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=34873"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=34873"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=34873"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}